BACKGROUND: Too few patients with nonvalvular atrial fibrillation (NVAF) receive appropriate antithrombotic therapy. We tested the short-term (primary outcome) and long-term (secondary outcome) effect of a patient decision aid on the appropriateness of antithrombotic therapy among patients with NVAF. METHODS: We conducted a cluster randomized trial with blinded outcome assessment involving 434 NVAF patients from 102 community-based primary care practices. Patients in the intervention group received a self-administered booklet and audiotape decision aid tailored to their personal stroke risk profile. Patients in the control group received usual care. The primary outcome measure was change in antithrombotic therapy at 3 months. Appropriateness of therapy was defined using the American College of Chest Physicians (ACCP) recommendations. RESULTS: The mean patient age was 72 years, and the median duration of NVAF was 5 years. In the control group, there was a 3% decrease over 3 months in the number of patients receiving therapy appropriate to their risk of stroke (40% [85/215] at baseline v. 37% [79/215] at 3 months). In the intervention group, the number of patients receiving therapy appropriate to their stroke risk increased by 9% (32% [69/219] at baseline v. 41% [89/219] at 3 months). Although the proportion of patients whose therapy met the ACCP treatment recommendations did not differ between study arms at baseline (p = 0.11) or 3 months (p = 0.44), there was a 12% absolute improvement in the number of patients receiving appropriate care in the intervention group compared with the control group at 3 months (p = 0.03). The beneficial effect of the decision aid did not persist (p = 0.44 for differences between study arms after 12 months). INTERPRETATION: There was short-term improvement in the appropriateness of antithrombotic care among patients with NVAF who were exposed to a decision aid, but the improvement did not persist.
RCT Entities:
BACKGROUND: Too few patients with nonvalvular atrial fibrillation (NVAF) receive appropriate antithrombotic therapy. We tested the short-term (primary outcome) and long-term (secondary outcome) effect of a patient decision aid on the appropriateness of antithrombotic therapy among patients with NVAF. METHODS: We conducted a cluster randomized trial with blinded outcome assessment involving 434 NVAF patients from 102 community-based primary care practices. Patients in the intervention group received a self-administered booklet and audiotape decision aid tailored to their personal stroke risk profile. Patients in the control group received usual care. The primary outcome measure was change in antithrombotic therapy at 3 months. Appropriateness of therapy was defined using the American College of Chest Physicians (ACCP) recommendations. RESULTS: The mean patient age was 72 years, and the median duration of NVAF was 5 years. In the control group, there was a 3% decrease over 3 months in the number of patients receiving therapy appropriate to their risk of stroke (40% [85/215] at baseline v. 37% [79/215] at 3 months). In the intervention group, the number of patients receiving therapy appropriate to their stroke risk increased by 9% (32% [69/219] at baseline v. 41% [89/219] at 3 months). Although the proportion of patients whose therapy met the ACCP treatment recommendations did not differ between study arms at baseline (p = 0.11) or 3 months (p = 0.44), there was a 12% absolute improvement in the number of patients receiving appropriate care in the intervention group compared with the control group at 3 months (p = 0.03). The beneficial effect of the decision aid did not persist (p = 0.44 for differences between study arms after 12 months). INTERPRETATION: There was short-term improvement in the appropriateness of antithrombotic care among patients with NVAF who were exposed to a decision aid, but the improvement did not persist.
Authors: Carl van Walraven; Robert G Hart; Daniel E Singer; Andreas Laupacis; Stuart Connolly; Palle Petersen; Peter J Koudstaal; Yuchiao Chang; Beppie Hellemons Journal: JAMA Date: 2002-11-20 Impact factor: 56.272
Authors: C Lerman; B Biesecker; J L Benkendorf; J Kerner; A Gomez-Caminero; C Hughes; M M Reed Journal: J Natl Cancer Inst Date: 1997-01-15 Impact factor: 13.506
Authors: Finlay A McAlister; Miriam Fradette; Sumit R Majumdar; Randall Williams; Michelle Graham; James McMeekin; William A Ghali; Ross T Tsuyuki; Merril L Knudtson; Jeremy Grimshaw Journal: CMAJ Date: 2009-11-23 Impact factor: 8.262
Authors: Finlay A McAlister; Sumit R Majumdar; Rajdeep S Padwal; Miriam Fradette; Ann Thompson; Ross Tsuyuki; Steven A Grover; Naeem Dean; Ashfaq Shuaib Journal: Implement Sci Date: 2010-04-12 Impact factor: 7.327
Authors: Michael R Gionfriddo; Aaron L Leppin; Juan P Brito; Annie Leblanc; Nilay D Shah; Victor M Montori Journal: J Comp Eff Res Date: 2013-11 Impact factor: 1.744
Authors: Liana Fraenkel; Richard L Street; Virginia Towle; John R O'Leary; Lynne Iannone; Peter H Van Ness; Terri R Fried Journal: J Am Geriatr Soc Date: 2012-08-02 Impact factor: 5.562
Authors: Melina Gattellari; Dominic Y Leung; Obioha C Ukoumunne; Nicholas Zwar; Jeremy Grimshaw; John M Worthington Journal: Implement Sci Date: 2011-05-20 Impact factor: 7.327